UK – NICE refuses Keytruda, Inlyta cancer combo

The National Institute for Health and Care Excellence (NICE) has released a draft guidance rejecting MSD’s Keytruda (pembrolizumab) when used in combo with Pfizer’s Inlyta (axitinib) to treat advanced renal cell carcinoma (RCC).

NICE already routinely commissions various drugs for first-line treatment of RCC, including Aveo’s Fotivda (tivozanib), Pfizer’s Sutent (sunitinib) and an Opdivo (nivolumab) Yervoy (ipilimumab) combination – the latter being through the Cancer Drugs Fund.

The organisation says that despite evidence suggesting that the Keytruda combo would be welcomed by patients, there was uncertainty around the long-term benefit. The organisation also cited inadequate clinical and cost-effectiveness as reasons for not recommending the drugs.

NICE reminds that Keytruda is given intravenously every three weeks and Inlyta is taken orally twice a day, with list prices of £2,630 per vial (100 mg) and £3,517 for 56 tablets (5 mg), respectively…